Radiotherapy News and Research RSS Feed - Radiotherapy News and Research

Radiation therapy (in North America), or radiotherapy (in the UK and Australia) also called radiation oncology, and sometimes abbreviated to XRT, is the medical use of ionizing radiation as part of cancer treatment to control malignant cells (not to be confused with radiology, the use of radiation in medical imaging and diagnosis).

GenSpera enrolls first patient in Phase II trial of compound G-202 in patients with glioblastoma multiforme

GenSpera, Inc. (OTCQB:GNSZ) announced that the first patient was enrolled in the Phase II clinical trial of its lead compound, G-202, in patients who have glioblastoma multiforme (GBM), the most prevalent type of primary brain cancer. [More]
Researchers identify two novel genes associated with development of rare, aggressive blood cancer

Researchers identify two novel genes associated with development of rare, aggressive blood cancer

R​esearchers have identified two novel cancer genes that are associated with the development of a rare, highly aggressive, cancer of blood vessels. These genes may now act as markers for future treatments and explain why narrowly targeted therapies that are directed at just one target fail. [More]

Plymouth University enters partnership with Brain Tumour Research

Patients, carers, scientists, clinicians and charities from across the UK are heading to Westminster today for the launch of a ground-breaking new collaborative partnership between the charity Brain Tumour Research and Plymouth University Peninsula Schools of Medicine and Dentistry. The announcement will open a new chapter in long-term sustainable and continuous research into the biggest cancer killer of children and adults under 40. [More]

Plymouth becomes active research partner with Brain Tumour Research

Plymouth University Peninsula Schools of Medicine and Dentistry will now become an active research and fundraising partner with Brain Tumour Research. The charity will support research and supply dedicated members of staff with expertise in fundraising, marketing and PR to work at both local and national levels alongside existing teams, creating a dynamic fundraising programme. [More]
Advanced Accelerator Applications agrees to acquire 100% shares of Imaging Equipment

Advanced Accelerator Applications agrees to acquire 100% shares of Imaging Equipment

Advanced Accelerator Applications, a fast growing international specialist in Molecular Nuclear Medicine (MNM), announced today that it has entered into an agreement to acquire 100% of the shares of Imaging Equipment Ltd, a privately-held UK distributor of nuclear medicine products and technologies, in newly issued AAA shares. [More]
Yangon General Hospital first to install Varian technology for cancer treatment

Yangon General Hospital first to install Varian technology for cancer treatment

Yangon General Hospital has become the first clinical site in Myanmar to install new technology from Varian Medical Systems (NYSE: VAR) for treating cancer with radiotherapy. [More]

Research: Pelvic cancer patients want to be better informed about side effects before treatment

Patients who undergo radiotherapy for pelvic cancers want to be better informed about side effects before treatment, research has revealed. [More]

Avoiding cSMG during radiation therapy is safe in head and neck cancer patients

Avoiding the contralateral submandibular gland during radiation therapy is feasible and safe with advanced stage, node positive head and neck cancers and base of tongue lesions, according to research presented today at the 2014 Multidisciplinary Head and Neck Cancer Symposium. [More]
CBTH intervention may reduce fatigue in breast cancer patients undergoing radiotherapy

CBTH intervention may reduce fatigue in breast cancer patients undergoing radiotherapy

Breast cancer patients receiving radiotherapy showed decreased fatigue as a result of cognitive behavioral therapy plus hypnosis (CBTH), according to a study recently published in the Journal of Clinical Oncology. [More]

Humidification of mouth during radiotherapy reduces hospital stay, mucositis in head, neck cancer patients

Patients who received daily humidification of the mouth and throat region beginning from day one of radiation therapy treatment spent nearly 50 percent fewer days in the hospital to manage their side effects, according to research presented today at the 2014 Multidisciplinary Head and Neck Cancer Symposium. [More]

Guerbet: FDA approves manufacturing plant for Lipiodol (ethiodized oil) Injection

Guerbet (GBT), the contrast agent specialist for medical imaging, today announced that it had received approval from the U.S. Food and Drug Administration (FDA) for a new manufacturing plant for Lipiodol® (ethiodized oil) Injection, in Montreal, Canada. [More]

Breast cancer patients receiving radiotherapy show decreased fatigue as result of CBTH

Breast cancer patients receiving radiotherapy showed decreased fatigue as a result of cognitive behavioral therapy plus hypnosis (CBTH), according to a study recently published in the Journal of Clinical Oncology. [More]
BMG Pharma signs agreement with Samyang Biopharmaceutical to market GelX in South Korea

BMG Pharma signs agreement with Samyang Biopharmaceutical to market GelX in South Korea

BMG Pharma S.r.l. today is pleased to announce that it has signed an exclusive distribution agreement with Samyang Biopharmaceutical Corporation granting them the rights to promote, sell and market its novel mucositis management product GelX in the territory of South Korea. [More]
New approach for treating leukemia

New approach for treating leukemia

A group of researchers at the Institute for Research in Immunology and Cancer (IRIC) of Université de Montréal discovered a promising new approach to treating leukemia by disarming a gene that is responsible for tumor progression. [More]

Researchers discover promising new approach for leukemia treatment

A group of researchers at the Institute for Research in Immunology and Cancer of Universit- de Montr-al discovered a promising new approach to treating leukemia by disarming a gene that is responsible for tumor progression. That gene, known as Brg1 is a key regulator of leukemia stem cells that are the root cause of the disease, resistance to treatment and relapse. [More]

Severe skin reactions during radiation therapy could be prevented by applying silicone dressing

Severe skin reactions during radiation therapy could be prevented by applying a thin transparent silicone dressing to the skin from the first day of treatment, clinical research from New Zealand shows. [More]
Understanding genetic changes associated with aggressive prostate cancer

Understanding genetic changes associated with aggressive prostate cancer

Researchers at the University of East Anglia have made an important advance in understanding genetic changes associated with terminal prostate cancer. [More]
Scientists discover potential cure for triple negative breast cancer

Scientists discover potential cure for triple negative breast cancer

Scientists have discovered a potential cure for one of the most aggressive and least treatable forms of breast cancer called "triple negative breast cancer." In laboratory experiments involving human cancer cells, scientists used a virus similar to the one that helped eradicate smallpox to coax cancer cells to produce a protein which makes them susceptible to radioactive iodine. [More]

Study: Combination treatment more than halves mortality rates for prostate cancer

Combination treatment more than halves mortality rates for prostate cancer, reports Norwegian health journal Dagens Medisin. [More]
Researchers identify therapeutic target for cervix cancer

Researchers identify therapeutic target for cervix cancer

Gene related to the proliferation of cancerous cells blocked through molecular technology. A group of researchers from Mexico's General Hospital, Health Secretariat, Medicine Faculty and the Institute of Cellular Physiology of the National Autonomous University of Mexico (UNAM) identified a therapeutic target for cervix cancer: gene CDKN3. [More]